Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2022) · doi:10.1101/2022.06.17.496443 · Cited by 1,833
Plasma proteomic associations with genetics and health in the UK Biobank
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2023) · Nature · doi:10.1038/s41586-023-06592-6 · Cited by 1,880
Rare variant contribution to human disease in 281,104 UK Biobank exomes
Wang, Q., Dhindsa, R. S., Carss, K., Harper, A. R., Nag, A., Tachmazidou, I., Vitsios, D., Deevi, S. V. V., Mackay, A., Muthas, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03855-y · Cited by 604
Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., Fumis, L., Miranda, A., Carvalho-Silva, D., Buniello, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa840 · Cited by 615
Open Targets Platform: supporting systematic drug–target identification and prioritisation
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1027 · Cited by 495
The next-generation Open Targets Platform: reimagined, redesigned, rebuilt
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., Lopez, I., Miranda, A., Cruz-Castillo, C., Fumis, L., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1046 · Cited by 432
Hautakangas, H., Winsvold, B. S., Ruotsalainen, S. E., Bjornsdottir, G., Harder, A. V. E., Kogelman, L. J. A., Thomas, L. F., Noordam, R., Benner, C., Gormley, P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-00990-0 · Cited by 398
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00885-0 · Cited by 401
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Refining the impact of genetic evidence on clinical success
Minikel, E. V., Painter, J. L., Dong, C. C., & Nelson, M. R. (2024) · Nature · doi:10.1038/s41586-024-07316-0 · Cited by 337
Interpretation of risk loci from genome-wide association studies of Alzheimer's disease
Andrews, S. J., Fulton-Howard, B., & Goate, A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30435-1 · Cited by 314
Utilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Robertson, C. C., Inshaw, J. R. J., Onengut-Gumuscu, S., Chen, W.-M., Santa Cruz, D. F., Yang, H., Cutler, A. J., Crouch, D. J. M., Farber, E., Bridges, S. L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00880-5 · Cited by 302
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 133
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Locus for severity implicates CNS resilience in progression of multiple sclerosis
International Multiple Sclerosis Genetics Consortium, Harroud, A., Stridh, P., McCauley, J. L., Saarela, J., van den Bosch, A. M. R., Engelenburg, H. J., Beecham, A. H., Alfredsson, L., Alikhani, K., et al. (2023) · Nature · doi:10.1038/s41586-023-06250-x · Cited by 285
Rabe, K. F., Celli, B. R., Wechsler, M. E., Abdulai, R. M., Luo, X., Boomsma, M. M., Staudinger, H., Horowitz, J. E., Baras, A., Ferreira, M. A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00167-3 · Cited by 232
Whole-genome sequencing of 490,640 UK Biobank participants
Manuscript Writing Group, Carss, K., Halldórsson, B. V., Hou, L., Liu, J. Z., Wheeler, E., Lo, Y., Kundu, K., Huang, Z., Lacey, B., et al. (2025) · Nature · doi:10.1038/s41586-025-09272-9 · Cited by 313
Synergistic insights into human health from aptamer- and antibody-based proteomic profiling
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Kerrison, N. D., Oerton, E., Koprulu, M., Luan, J., Hingorani, A. D., Williams, S. A., Wareham, N. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27164-0 · Cited by 234
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 220
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A., Fitzgerald, K., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 207
Storm, C. S., Kia, D. A., Almramhi, M. M., Bandres-Ciga, S., Finan, C., International Parkinson’s Disease Genomics Consortium (IPDGC), Noyce, A. J., Kaiyrzhanov, R., Middlehurst, B., Tan, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26280-1 · Cited by 208
Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants
Crouch, D. J. M., & Bodmer, W. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005634117 · Cited by 193
Shared mechanisms across the major psychiatric and neurodegenerative diseases
Wingo, T. S., Liu, Y., Gerasimov, E. S., Vattathil, S. M., Wynne, M. E., Liu, J., Lori, A., Faundez, V., Bennett, D. A., Seyfried, N. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31873-5 · Cited by 190
Translational genomics and precision medicine: Moving from the lab to the clinic
Zeggini, E., Gloyn, A. L., Barton, A. C., & Wain, L. V. (2019) · Science · doi:10.1126/science.aax4588 · Cited by 185
Multi-modality machine learning predicting Parkinson’s disease
Makarious, M. B., Leonard, H. L., Vitale, D., Iwaki, H., Sargent, L., Dadu, A., Violich, I., Hutchins, E., Saffo, D., Bandres-Ciga, S., et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00288-w · Cited by 158
Evaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 187
Chauquet, S., Zhu, Z., O’Donovan, M. C., Walters, J. T. R., Wray, N. R., & Shah, S. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0005 · Cited by 178
From variant to function in human disease genetics
Lappalainen, T., & MacArthur, D. G. (2021) · Science · doi:10.1126/science.abi8207 · Cited by 173
UK Biobank: a globally important resource for cancer research
Conroy, M. C., Lacey, B., Bešević, J., Omiyale, W., Feng, Q., Effingham, M., Sellers, J., Sheard, S., Pancholi, M., Gregory, G., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02053-5 · Cited by 168
The genetics of asthma and the promise of genomics-guided drug target discovery
El-Husseini, Z. W., Gosens, R., Dekker, F., & Koppelman, G. H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30363-5 · Cited by 161
A review of biomedical datasets relating to drug discovery: a knowledge graph perspective
Bonner, S., Barrett, I. P., Ye, C., Swiers, R., Engkvist, O., Bender, A., Hoyt, C. T., & Hamilton, W. L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac404 · Cited by 197
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
Downes, D. J., Cross, A. R., Hua, P., Roberts, N., Schwessinger, R., Cutler, A. J., Munis, A. M., Brown, J., Mielczarek, O., de Andrea, C. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00955-3 · Cited by 173
Insights from multi-omics integration in complex disease primary tissues
Kreitmaier, P., Katsoula, G., & Zeggini, E. (2023) · Trends in Genetics · doi:10.1016/j.tig.2022.08.005 · Cited by 161
Su, W.-M., Gu, X.-J., Dou, M., Duan, Q.-Q., Jiang, Z., Yin, K.-F., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y.-P. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331142 · Cited by 161
Emdin, C. A., Haas, M. E., Khera, A. V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.-Q., Feng, Q., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008629 · Cited by 161
A disease-associated gene desert directs macrophage inflammation through ETS2
Stankey, C. T., Bourges, C., Haag, L. M., Turner-Stokes, T., Piedade, A. P., Palmer-Jones, C., Papa, I., Silva dos Santos, M., Zhang, Q., Cameron, A. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07501-1 · Cited by 158
Unique roles of rare variants in the genetics of complex diseases in humans
Momozawa, Y., & Mizukami, K. (2021) · Journal of Human Genetics · doi:10.1038/s10038-020-00845-2 · Cited by 161
Sheng, X., Guan, Y., Ma, Z., Wu, J., Liu, H., Qiu, C., Vitale, S., Miao, Z., Seasock, M. J., Palmer, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00909-9 · Cited by 157
Burgess, S., Mason, A. M., Grant, A. J., Slob, E. A. W., Gkatzionis, A., Zuber, V., Patel, A., Tian, H., Liu, C., Haynes, W. G., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.017 · Cited by 174
Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets
Sierksma, A., Escott-Price, V., & De Strooper, B. (2020) · Science · doi:10.1126/science.abb8575 · Cited by 146
Biological and functional multimorbidity—from mechanisms to management
Langenberg, C., Hingorani, A. D., & Whitty, C. W. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02420-6 · Cited by 166
Genetic architecture of host proteins involved in SARS-CoV-2 infection
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Raffler, J., Kerrison, N. D., Oerton, E., Auyeung, V. P. W., Luan, J., Finan, C., Casas, J. P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19996-z · Cited by 143
Genetic associations of protein-coding variants in human disease
Sun, B. B., Kurki, M. I., Foley, C. N., Mechakra, A., Chen, C.-Y., Marshall, E., Wilk, J. B., Biogen Biobank Team, Sun, B. B., Ghen, C.-Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04394-w · Cited by 147
Costanzo, M. C., von Grotthuss, M., Massung, J., Jang, D., Caulkins, L., Koesterer, R., Gilbert, C., Welch, R., Kudtarkar, P., Hoang, Q., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.001 · Cited by 147
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
Single-cell genomics meets human genetics
Cuomo, A. S. E., Nathan, A., Raychaudhuri, S., MacArthur, D. G., & Powell, J. E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00599-5 · Cited by 124
WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders
Huybrechts, Y., Mortier, G. R., Boudin, E., & Hul, W. V. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00165 · Cited by 140
Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H., Yang, W., van der Meer, D., Shepherd, R., Pignatelli, M., Iorio, F., & Garnett, M. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa882 · Cited by 120
Genetics of multiple sclerosis: lessons from polygenicity
Goris, A., Vandebergh, M., McCauley, J. L., Saarela, J., & Cotsapas, C. J. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00255-1 · Cited by 127
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
Iwaki, H., Leonard, H. L., Makarious, M. B., Bookman, M., Landin, B., Vismer, D., Casey, B., Gibbs, J. R., Hernandez, D. G., Blauwendraat, C., et al. (2021) · Movement Disorders · doi:10.1002/mds.28549 · Cited by 116
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Cao, Y., Yang, Y., Hu, Q., & Wei, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04474-z · Cited by 129
A Mendelian randomization study investigating the causal role of inflammation on Parkinson’s disease
Bottigliengo, D., Foco, L., Seibler, P., Klein, C., König, I. R., & Fabiola Del Greco, M. (2022) · Brain · doi:10.1093/brain/awac193 · Cited by 114
Dissecting polygenic signals from genome-wide association studies on human behaviour
Abdellaoui, A., & Verweij, K. J. H. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01110-y · Cited by 114
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
Gorski, M., Jung, B., Li, Y., Matías‐García, P. R., Wuttke, M., Coassin, S., Thio, C. H. L., Kleber, M. E., Winkler, T. W., Wanner, V., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.030 · Cited by 109
The Singapore National Precision Medicine Strategy
Wong, E., Bertin, N., Hebrard, M., Tirado-Magallanes, R., Bellis, C., Lim, W. K., Chua, C. Y., Tong, P. M. L., Chua, R., Mak, K. S. W., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01274-x · Cited by 111
Decoding the genetic and epigenetic basis of asthma
Stikker, B., Hendriks, R. W., & Stadhouders, R. (2023) · Allergy · doi:10.1111/all.15666 · Cited by 103
Redd, M. A., Scheuer, S. E., Saez, N. J., Yoshikawa, Y., Chiu, H. S., Gao, L., Hicks, M., Villanueva, J. E., Joshi, Y., Chow, C. Y., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054360 · Cited by 101
Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE): A Review
Markus, H. S., van der Flier, W. M., Smith, E. E., Bath, P. M., Biessels, G. J., Briceño, E. M., Brodtman, A., Chabriat, H., Chen, C., de Leeuw, F., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2262 · Cited by 95
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 100
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Jensen, L. T., Attfield, K. E., Feldmann, M., & Fugger, L. H. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104840 · Cited by 91
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 104
Genetics of Intracranial Aneurysms
Bakker, M. K., & Ruigrok, Y. M. (2021) · Stroke · doi:10.1161/strokeaha.120.032621 · Cited by 83
Alsheikh, A. J., Wollenhaupt, S., King, E. A., Reeb, J., Ghosh, S., Stolzenburg, L. R., Tamim, S., Lazar, J., Davis, J. W., & Jacob, H. J. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01216-w · Cited by 89
Self-citationMulti-ancestry meta-analysis and fine-mapping in Alzheimer’s disease
Lake, J., Solsberg, C. W., Kim, J. J., Acosta‐Uribe, J., Makarious, M. B., Li, Z., Levine, K. S., Heutink, P., Alvarado, C. X., Vitale, D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02089-w · Cited by 90
Sequential immunotherapy: towards cures for autoimmunity
Ramírez‐Valle, F., Maranville, J., Roy, S., & Plenge, R. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00959-8 · Cited by 85
Baird, D. A., Liu, J. Z., Zheng, J., Sieberts, S. K., Perumal, T., Elsworth, B., Richardson, T. G., Chen, C.-Y., Carrasquillo, M. M., Allen, M., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009224 · Cited by 83
Next-generation drug repurposing using human genetics and network biology
Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 75
An effector index to predict target genes at GWAS loci
Forgetta, V., Jiang, L., Vulpescu, N. A., Hogan, M. S., Chen, S., Morris, J. A., Grinek, S., Benner, C., Jang, D., Hoang, Q., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02434-z · Cited by 79
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Kibinge, N. K., Relton, C. L., Gaunt, T. R., & Richardson, T. G. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.04.007 · Cited by 71
A catalog of GWAS fine-mapping efforts in autoimmune disease
Çalışkan, M., Brown, C. D., & Maranville, J. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.009 · Cited by 76
Molecular genetics of cocaine use disorders in humans
Fernàndez‐Castillo, N., Cabana‐Domínguez, J., Corominas, R., & Cormand, B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01256-1 · Cited by 80
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
Namba, S., Konuma, T., Wu, K.-H., Zhou, W., Initiative, G. B. M.-A., & Okada, Y. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100190 · Cited by 75
Mendelian randomization as a tool to inform drug development using human genetics
Daghlas, I., & Gill, D. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5 · Cited by 72
The genetic basis for adult onset glaucoma: Recent advances and future directions
Wang, Z., Wiggs, J. L., Aung, T., Khawaja, A. P., & Khor, C. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101066 · Cited by 71
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
Deaton, A. M., Dubey, A., Ward, L. D., Dornbos, P., Flannick, J., AMP-T2D-GENES Consortium, Yee, E., Ticau, S., Noetzli, L., Parker, M. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31757-8 · Cited by 57
Raies, A., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D. (2022) · Communications Biology · doi:10.1038/s42003-022-04245-4 · Cited by 61
Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension
Rhodes, C. J., Sweatt, A. J., & Maron, B. A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319969 · Cited by 64
Immune dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100108 · Cited by 63
Mukhi, D., Li, L., Liu, H., Doke, T., Kolligundla, L. P., Ha, E., Kloetzer, K. A., Abedini, A., Mukherjee, S., Wu, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172963 · Cited by 64
Genetic factors associated with reasons for clinical trial stoppage
Razuvayevskaya, O., López, I., Dunham, I., & Ochoa, D. (2024) · Nature Genetics · doi:10.1038/s41588-024-01854-z · Cited by 66
Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy
Ghodke‐Puranik, Y., Olferiev, M., & Crow, M. K. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01152-2 · Cited by 72
Gorski, M., Rasheed, H., Teumer, A., Thomas, L. F., Graham, S. E., Sveinbjörnsson, G., Winkler, T. W., Günther, F., Stark, K. J., Chai, J. F., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.021 · Cited by 58
Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., the PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1003988 · Cited by 55
Advances in Genomics for Drug Development
Spreafico, R., Soriaga, L. B., Grosse, J., Virgin, H. W., & Telenti, A. (2020) · Genes · doi:10.3390/genes11080942 · Cited by 59
Genetics of chronic respiratory disease
Sayers, I., John, C., Chen, J., & Hall, I. P. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00695-0 · Cited by 55
Yoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Su, C., Chen, Y., Liang, K., Willett, J., Wang, S., Adra, D., et al. (2023) · Nature Genetics · doi:10.1016/j.cjca.2023.06.321 · Cited by 65
Genetics of eating disorders in the genome-wide era
Watson, H. J., Palmos, A. B., Hunjan, A. K., Baker, J. H., Yılmaz, Z., & Davies, H. L. (2021) · Psychological Medicine · doi:10.1017/s0033291720005474 · Cited by 61
Common pitfalls in drug target Mendelian randomization and how to avoid them
Gill, D., Dib, M., Cronjé, H. T., Karhunen, V., Woolf, B. A. R., Gagnon, É., Daghlas, I., Nyberg, M., Drakeman, D. L., & Burgess, S. (2024) · BMC Medicine · doi:10.1186/s12916-024-03700-9 · Cited by 60
Causal inference in drug discovery and development
Michoel, T., & Zhang, J. D. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103737 · Cited by 64
Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease
Mazidi, M., Wright, N., Yao, P., Kartsonaki, C., Millwood, I. Y., Fry, H., Said, S., Pozarickij, A., Pei, P., Chen, Y., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.804 · Cited by 57
Cary, G. A., Wiley, J. C., Gockley, J., Keegan, S., Amirtha Ganesh, S. S., Heath, L., Butler, R. R., Mangravite, L. M., Logsdon, B. A., Longo, F. M., et al. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12461 · Cited by 49
Artificial intelligence for dementia drug discovery and trials optimization
Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13428 · Cited by 48
A multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo, S., Vickers‐Smith, R., Jinwala, Z., Xu, H., Saini, D., Hartwell, E. E., Pavicic, M., Sullivan, K. A., Xu, K., Jacobson, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02839-5 · Cited by 56
Human genetics and epigenetics of alcohol use disorder
Zhou, H., & Gelernter, J. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172885 · Cited by 55
Tissue-specific genes as an underutilized resource in drug discovery
Ryaboshapkina, M., & Hammar, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-43829-9 · Cited by 61
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.